BIO KEY INTERNATIONAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIO KEY INTERNATIONAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $6.30M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $2.98M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $5.26M | Apr 4, 2017 |
| FY2015 | Dec 31, 2014 | $4.01M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $1.99M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $3.84M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $3.51M | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $3.52M | Apr 16, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.64M | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | $1.43M | Apr 23, 2025 |
| FY2024 | Sep 30, 2023 | $340.5K | Apr 23, 2025 |
| FY2024 | Jun 30, 2023 | $322.8K | Apr 23, 2025 |
| FY2024 | Mar 31, 2023 | $863.5K | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | $4.58M | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | $3.44M | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $2.04M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($193.7K) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($119.6K) | May 14, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.30M) | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | ($8.52M) | Apr 23, 2025 |
| FY2024 | Sep 30, 2023 | ($1.84M) | Apr 23, 2025 |
| FY2024 | Jun 30, 2023 | ($2.48M) | Apr 23, 2025 |
| FY2024 | Mar 31, 2023 | ($1.69M) | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | ($11.91M) | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | ($5.07M) | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | ($9.67M) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($14.59M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($6.87M) | May 14, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.01M) | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | ($8.83M) | Apr 23, 2025 |
| FY2024 | Sep 30, 2023 | ($1.97M) | Apr 23, 2025 |
| FY2024 | Jun 30, 2023 | ($2.38M) | Apr 23, 2025 |
| FY2024 | Mar 31, 2023 | ($1.76M) | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | ($9.92M) | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | ($4.94M) | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | ($5.20M) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($1.07M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $80 | May 14, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.51M | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | $2.39M | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | $3.25M | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | $2.36M | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.40M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.33M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.42M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.66M | Apr 5, 2019 |
| FY2017 | Dec 31, 2016 | $2.01M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $1.56M | Apr 4, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.14M | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | $7.86M | Apr 23, 2025 |
| FY2023 | Sep 30, 2023 | $1.75M | Jun 5, 2024 |
| FY2024 | Jun 30, 2023 | $1.75M | Apr 23, 2025 |
| FY2024 | Mar 31, 2023 | $2.14M | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | $9.36M | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | $6.03M | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $5.85M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $5.04M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $5.33M | May 14, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($2.91M) | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | ($3.79M) | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | ($6.23M) | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | ($8.98M) | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | ($4.95M) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($1.85M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($1.61M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($2.47M) | Apr 5, 2019 |
| FY2017 | Dec 31, 2016 | ($4.45M) | Apr 2, 2018 |
| FY2015 | Dec 31, 2015 | ($15.56M) | Mar 30, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $13.0K | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | $1.0K | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | $82.0K | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | $42.0K | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $35.6K | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $28.8K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $52.1K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $166.1K | Apr 5, 2019 |
| FY2017 | Dec 31, 2016 | $53.0K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $3.4K | Apr 4, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $8.62M | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | $4.52M | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | $11.34M | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | $17.77M | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $22.52M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $2.50M | Mar 29, 2021 |
| FY2019 | Jan 1, 2019 | $12.28M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $11.69M | May 14, 2020 |
| FY2018 | Jan 1, 2018 | $16.32M | Apr 5, 2019 |
| FY2018 | Dec 31, 2017 | $16.08M | Apr 5, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.84M | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | $3.45M | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | $6.04M | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | $2.15M | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $2.19M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $4.78M | Mar 29, 2021 |
| FY2019 | Jan 1, 2019 | $1.82M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $1.23M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $2.33M | Apr 5, 2019 |
| FY2017 | Dec 31, 2016 | $1.84M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.77M | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | $1.06M | Apr 23, 2025 |
| FY2024 | Sep 30, 2023 | ($485.5K) | Apr 23, 2025 |
| FY2024 | Jun 30, 2023 | $1.25M | Apr 23, 2025 |
| FY2024 | Mar 31, 2023 | $3.76M | Apr 23, 2025 |
| FY2024 | Dec 31, 2022 | $5.30M | Apr 23, 2025 |
| FY2023 | Dec 31, 2021 | $15.62M | Jun 5, 2024 |
| FY2022 | Dec 31, 2020 | $20.34M | Jun 1, 2023 |
| FY2021 | Dec 31, 2019 | ($2.29M) | Apr 1, 2022 |
| FY2020 | Dec 31, 2018 | $10.47M | Mar 29, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Jun 1, 2023 |
| FY2022 | Dec 31, 2021 | $1.26M | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.26M | Apr 1, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($129.31M) | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | ($125.01M) | Apr 23, 2025 |
| FY2024 | Sep 30, 2023 | ($122.63M) | Apr 23, 2025 |
| FY2024 | Jun 30, 2023 | ($120.80M) | Apr 23, 2025 |
| FY2024 | Mar 31, 2023 | ($118.17M) | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | ($116.49M) | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | ($104.58M) | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | ($99.51M) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($89.72M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($75.13M) | May 14, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $437.6K | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | $511.4K | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | $2.64M | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | $7.75M | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $16.99M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $79.0K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $323.9K | May 14, 2020 |
| FY2019 | Dec 31, 2017 | $288.7K | May 14, 2020 |
| FY2018 | Dec 31, 2016 | $1.06M | Apr 5, 2019 |
| FY2017 | Dec 31, 2015 | $4.32M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (2) | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | (15) | Apr 23, 2025 |
| FY2024 | Sep 30, 2023 | (3) | Apr 23, 2025 |
| FY2024 | Jun 30, 2023 | (4) | Apr 23, 2025 |
| FY2024 | Mar 31, 2023 | (3) | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | (27) | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Jun 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 3.72M | Apr 23, 2025 |
| FY2024 | Dec 31, 2023 | 1.03M | Apr 23, 2025 |
| FY2023 | Dec 31, 2022 | 552,739 | Jun 5, 2024 |
| FY2022 | Dec 31, 2021 | 7.85M | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | 7.81M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | 1.81M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 13.98M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | 7.69M | Apr 5, 2019 |
| FY2017 | Dec 31, 2016 | 6.09M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 5.51M | Apr 4, 2017 |